

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplement table S1. Reported gene amplifications from ovarian cancer tumours

Gene (amplification)	Count (n=1.022)	% of all amplifications (n=1.022)	% of 336
<i>PIK3CA</i>	115	11.3%	34.2%
<i>MYC</i>	83	8.1%	24.7%
<i>ALK</i>	77	7.5%	22.9%
<i>EGFR</i>	67	6.6%	19.9%
<i>CCNE1</i>	56	5.5%	16.7%
<i>KRAS</i>	43	4.2%	12.8%
<i>PIK3CB</i>	35	3.4%	10.4%
<i>FGF23</i>	34	3.3%	10.1%
<i>MYCL</i>	33	3.2%	9.8%
<i>FGFR1</i>	29	2.8%	8.6%
<i>AKT2</i>	28	2.7%	8.3%
<i>MET</i>	27	2.6%	8.0%
<i>BRAF</i>	26	2.5%	7.7%
<i>AKT3</i>	23	2.3%	6.8%
<i>CCND1</i>	23	2.3%	6.8%
<i>FGFR2</i>	19	1.9%	5.7%
<i>CCND3</i>	18	1.8%	5.4%
<i>MDM4</i>	18	1.8%	5.4%
<i>MYCN</i>	18	1.8%	5.4%
<i>NTRK1</i>	17	1.7%	5.1%
<i>ERBB2</i>	16	1.6%	4.8%
<i>ERBB3</i>	15	1.5%	4.5%
<i>JAK2</i>	15	1.5%	4.5%
<i>CDK6</i>	13	1.3%	3.9%
<i>FGF19</i>	13	1.3%	3.9%
<i>BRD4</i>	12	1.2%	3.6%
<i>CDK4</i>	11	1.1%	3.3%
<i>FGFR4</i>	10	1.0%	3.0%
<i>MDM2</i>	10	1.0%	3.0%
<i>DDR2</i>	9	0.9%	2.7%
<i>FGF3</i>	9	0.9%	2.7%
<i>FGF4</i>	9	0.9%	2.7%
<i>AKT1</i>	8	0.8%	2.4%
<i>CCND2</i>	7	0.7%	2.1%
<i>KIT</i>	7	0.7%	2.1%
<i>PDGFRA</i>	7	0.7%	2.1%
<i>FGF1</i>	6	0.6%	1.8%
<i>RICTOR</i>	6	0.6%	1.8%
<i>FGFR3</i>	5	0.5%	1.5%
<i>HRAS</i>	5	0.5%	1.5%
<i>JUN</i>	5	0.5%	1.5%
<i>CD274</i>	4	0.4%	1.2%
<i>FGF8</i>	4	0.4%	1.2%
<i>ROS1</i>	4	0.4%	1.2%
<i>FGF7</i>	3	0.3%	0.9%
<i>MITF</i>	3	0.3%	0.9%
<i>CRLF2</i>	2	0.2%	0.6%

<i>EZH2</i>	2	0.2%	0.6%
<i>FGF2</i>	2	0.2%	0.6%
<i>FGF9</i>	2	0.2%	0.6%
<i>KDR</i>	2	0.2%	0.6%
<i>RAF1</i>	2	0.2%	0.6%
<i>AR</i>	1	0.1%	0.3%
<i>ETV1</i>	1	0.1%	0.3%
<i>MAPK1</i>	1	0.1%	0.3%
<i>MYB</i>	1	0.1%	0.3%
<i>MYCL1</i>	1	0.1%	0.3%

Supplement table S2. Reported gene deletions from ovarian cancer tumours

Gene (deletion)	count (n=129)	% from all deletions (n=129)	% of 336 tumors
<i>STK11</i>	18	14.0%	5.4%
<i>NF1</i>	12	9.3%	3.6%
<i>CDH1</i>	10	7.8%	3.0%
<i>ATRX</i>	9	7.0%	2.7%
<i>KDM6A</i>	9	7.0%	2.7%
<i>NF2</i>	8	6.2%	2.4%
<i>CDK12</i>	7	5.4%	2.1%
<i>IKZF1</i>	7	5.4%	2.1%
<i>DICER1</i>	6	4.7%	1.8%
<i>ARID1A</i>	5	3.9%	1.5%
<i>SMAD4</i>	5	3.9%	1.5%
<i>ATM</i>	3	2.3%	0.9%
<i>CDKN2B</i>	3	2.3%	0.9%
<i>PAX5</i>	3	2.3%	0.9%
<i>SMARCA4</i>	3	2.3%	0.9%
<i>BARD1</i>	2	1.6%	0.6%
<i>BRCA1</i>	2	1.6%	0.6%
<i>BRCA2</i>	2	1.6%	0.6%
<i>CREBBP</i>	2	1.6%	0.6%
<i>FBXW7</i>	2	1.6%	0.6%
<i>SMARCB1</i>	2	1.6%	0.6%
<i>TP53</i>	2	1.6%	0.6%
<i>VHL</i>	2	1.6%	0.6%
<i>CDKN2A</i>	1	0.8%	0.3%
<i>FH</i>	1	0.8%	0.3%
<i>MLH1</i>	1	0.8%	0.3%
<i>PTEN</i>	1	0.8%	0.3%
<i>SETD2</i>	1	0.8%	0.3%

Supplement Table S3. Reported gene fusions from ovarian cancer tumours

Gene fusions	Count (n=18)	% of all fusions (n=18)	% of 336
<i>ESR1::CCDC170</i>	4	22.2%	1.2%
<i>ESR1::C6orf211</i>	2	11.1%	0.6%
<i>FIP1L1::PDGFRA</i>	2	11.1%	0.6%
<i>ESR1::ERBB2</i>	2	11.1%	0.6%
<i>BRAF::NDUFB2</i>	1	5.6%	0.3%
<i>CTTN::ERBB2</i>	1	5.6%	0.3%
<i>EWSR1::BRMS1L</i>	1	5.6%	0.3%
<i>FGFR2::SEC23IP</i>	1	5.6%	0.3%
<i>FGFR2::TACC2</i>	1	5.6%	0.3%
<i>IQGAP1::NTRK3</i>	1	5.6%	0.3%
<i>KANSL1L::ERBB4</i>	1	5.6%	0.3%
<i>KMT2A::BACE1</i>	1	5.6%	0.3%
<i>KMT2A::UBE4A</i>	1	5.6%	0.3%
<i>MAP3K2::ETV4</i>	1	5.6%	0.3%
<i>PRRC2B::ABL1</i>	1	5.6%	0.3%
<i>RCL1::JAK2</i>	1	5.6%	0.3%
<i>SEC16A::NOTCH1</i>	1	5.6%	0.3%
<i>ZMIZ1::BRAF</i>	1	5.6%	0.3%

Supplement table S4. Reported actionable variants in solid tumors according to OncoKB in the cohort

Actionable variants in solid tumors			
Genes with PV	Number	% of PV OncoKB in solid tumors	% of 336
<i>BRCA1</i>	50	28.9	14.9
<i>KRAS</i>	20	11.6	6.0
<i>BRCA2</i>	19	11.0	5.7
<i>PIK3CA</i>	17	9.8	5.1
<i>NF1</i>	13	7.5	3.9
<i>PTEN</i>	8	4.6	2.4
<i>BRIP1</i>	6	3.5	1.8
<i>CHEK2</i>	5	2.9	1.5
<i>ATM</i>	5	2.9	1.5
<i>NRAS</i>	4	2.3	1.2
<i>PALB2</i>	4	2.3	1.2
<i>BRAF</i> (V600)	3	1.7	0.9
<i>ERBB2</i>	3	1.7	0.9
<i>BARD1</i>	2	1.2	0.6
<i>FGFR2</i>	2	1.2	0.6
<i>NBN</i>	3	1.7	0.9
<i>TSC1</i>	2	1.2	0.6
<i>CDK12</i>	1	0.6	0.3
<i>CHEK1</i>	1	0.6	0.3
<i>ESR1</i>	1	0.6	0.3
<i>MRE11</i>	1	0.6	0.3
<i>RAD54L</i>	1	0.6	0.3
<i>TSC2</i>	1	0.6	0.3
<i>MAP2K1</i>	1	0.6	0.3
TOTAL	173	100%	51.5%
Amplifications			
<i>MET</i>	27	62.8%	8.0%
<i>ERBB2</i>	16	37.2%	4.8%
TOTAL	43	100%	12.8%
Deletions			
<i>SMARCB1</i>	2	100%	0.6%
TOTAL	2	100%	0.6%
Fusions			
<i>BRAF</i>	2	40.0%	0.6%
<i>FGFR2</i>	2	40.0%	0.6%
<i>NTRK3</i>	1	20.0%	0.3%
TOTAL	5	100%	1.2%
Tumor biomarkers			
TMB-HIGH	13	18.1%	3.9%
MSI-HIGH	9	12.5%	2.7%
HRD+	50	69.4%	14.9%

TOTAL	72	100%	21.4%
Total number of ovarian cancer tumor samples with at least one actionable variant	189	100%	56.3%